CLINICAL TRIALS PROFILE FOR HYTONE

All Clinical Trials for Hytone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	National Cancer Institute (NCI)	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00536991 ↗	Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer	Terminated	Roswell Park Cancer Institute	Phase 1/Phase 2	2006-10-01	This phase I/II trial studies the side effects and best dose of calcitriol when given in combination with ketoconazole and therapeutic hydrocortisone and to see how well it works in treating patients with prostate cancer. Calcitriol may help prostate cancer cells become more like normal cells and grow and spread more slowly. Ketoconazole and therapeutic hydrocortisone may help calcitriol work better by making tumor cells more sensitive to the drug. Giving calcitriol together with ketoconazole and therapeutic hydrocortisone may be a better treatment for prostate cancer.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
NCT00557193 ↗	Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	Active, not recruiting	Children's Oncology Group	Phase 3	2008-01-14	This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
NCT01867294 ↗	Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab	Completed	National Cancer Institute (NCI)	Phase 2	2012-08-31	This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.
NCT01867294 ↗	Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab	Completed	Academic and Community Cancer Research United	Phase 2	2012-08-31	This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.

Clinical Trial Conditions for Hytone

Condition Name

Condition Name for Hytone
Intervention	Trials
B Acute Lymphoblastic Leukemia	2
Acute Lymphoblastic Leukemia	2
Untreated Childhood Acute Lymphoblastic Leukemia	2
Diffuse Large B-Cell Lymphoma	1

Condition MeSH

Condition MeSH for Hytone
Intervention	Trials
Leukemia	4
Leukemia, Lymphoid	3
Precursor Cell Lymphoblastic Leukemia-Lymphoma	3
Burkitt Lymphoma	2

Clinical Trial Locations for Hytone

Trials by Country

Trials by Country for Hytone
Location	Trials
United States	213
Canada	30
Australia	5
New Zealand	5
Puerto Rico	3

Trials by US State

Trials by US State for Hytone
Location	Trials
Illinois	7
Wisconsin	6
Ohio	6
New York	6
Minnesota	6

Clinical Trial Progress for Hytone

Clinical Trial Phase

Clinical Trial Phase for Hytone
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for Hytone
Clinical Trial Phase	Trials
Active, not recruiting	4
Recruiting	2
Completed	1

Clinical Trial Sponsors for Hytone

Sponsor Name

Sponsor Name for Hytone
Sponsor	Trials
National Cancer Institute (NCI)	8
Children's Oncology Group	4
Northwestern University	1

Sponsor Type

Sponsor Type for Hytone
Sponsor	Trials
NIH	8
Other	8
Industry	1

Clinical Trials, Market Analysis, and Projections for Hytone and Similar Topical Treatments

Introduction to Hytone and Topical Treatments

Hytone, a brand of hydrocortisone cream or lotion, is widely used for various skin conditions, including atopic dermatitis, seborrheic dermatitis, and contact dermatitis. This article will delve into the current landscape of clinical trials, market analysis, and future projections for Hytone and similar topical treatments.

Clinical Trials Overview

Current State of Clinical Trials

Clinical trials for topical treatments like Hytone are ongoing, although the specific focus may vary. For instance, hydrocortisone, the active ingredient in Hytone, has been involved in numerous clinical trials across different phases. As of the latest data, hydrocortisone has been part of 16 Phase 0, 64 Phase 1, 142 Phase 2, 114 Phase 3, and 70 Phase 4 clinical trials[5].

Recent Trends in Clinical Trials

The global clinical trials market is growing significantly, driven by the increasing demand to treat chronic diseases. The number of registered trials has increased substantially in recent years, with many trials being conducted outside of the U.S. and the European Union due to cost-effectiveness and simpler regulatory processes[3].

Market Analysis for Topical Treatments

Market Size and Growth

The market for topical treatments, including those containing hydrocortisone, is substantial. The global clinical trials market, which includes trials for various treatments including topical ones, is projected to grow from $61.58 billion in 2024 to $106.78 billion by 2032, at a CAGR of 7.1%[3].

Consumer Preferences and Trends

Patients and physicians continue to show preference for over-the-counter (OTC) products that have transitioned from prescription status. This trend is driven by patient familiarity, widespread availability, and positive attitudes towards the efficacy and safety of these products. For example, the switch of 1% hydrocortisone from prescription to OTC status resulted in significant healthcare cost savings[2].

Hytone and Hydrocortisone: Usage and Recommendations

Common Skin Conditions Treated

Hytone is commonly recommended for various skin conditions, including:

• Atopic Dermatitis: Hydrocortisone is one of the most frequently recommended treatments, along with other products like Eucerin and Aveeno[2].
• Seborrheic Dermatitis: Hytone is among the top recommendations, alongside other treatments such as selenium sulfide shampoo and DHS Zinc[2].
• Contact Dermatitis: Hydrocortisone and calamine lotion are frequently used for this condition[2].

Mechanism of Action and Efficacy

Hydrocortisone, the active ingredient in Hytone, acts as a glucocorticoid receptor agonist, providing anti-inflammatory and immunosuppressive effects. It is highly effective in treating corticosteroid-responsive dermatoses, endocrine disorders, immune conditions, and allergic reactions[5].

Future Projections for Topical Treatments

Market Growth and Expansion

The market for topical treatments is expected to continue growing, driven by the increasing prevalence of chronic skin conditions and the preference for OTC products. The ease of access and cost-effectiveness of these treatments will likely contribute to their continued popularity.

Technological Advancements

Advancements in drug delivery systems and formulations are expected to enhance the efficacy and user experience of topical treatments. For example, technologies like Axsome's MoSEIC, which enables rapid absorption and longer plasma half-life, could be applied to future topical treatments[1].

Key Takeaways

• Clinical Trials: The number of clinical trials for topical treatments is increasing, with a significant focus on chronic diseases.
• Market Growth: The global market for clinical trials and topical treatments is projected to grow substantially by 2032.
• Consumer Preferences: Patients and physicians prefer OTC products due to their familiarity, availability, and cost-benefit.
• Hytone and Hydrocortisone: These remain popular treatments for various skin conditions due to their efficacy and safety profile.
• Future Projections: The market is expected to grow, driven by technological advancements and increasing demand.

FAQs

What is Hytone commonly used for?

Hytone is commonly used to treat various skin conditions such as atopic dermatitis, seborrheic dermatitis, and contact dermatitis.

How does hydrocortisone work?

Hydrocortisone acts as a glucocorticoid receptor agonist, providing anti-inflammatory and immunosuppressive effects.

What is the current market trend for topical treatments?

The market for topical treatments is growing, driven by the increasing prevalence of chronic skin conditions and the preference for OTC products.

Are there any technological advancements in topical treatments?

Yes, advancements in drug delivery systems and formulations, such as Axsome's MoSEIC technology, are expected to enhance the efficacy and user experience of topical treatments.

What is the projected growth of the clinical trials market?

The global clinical trials market is projected to grow from $61.58 billion in 2024 to $106.78 billion by 2032, at a CAGR of 7.1%.

Sources

1. HCPLive: 5 FDA Decisions to Watch in Q1 2025
2. MDedge: Over-the-Counter Topical Skin Products—A Common Component of ...
3. Fortune Business Insights: Clinical Trials Market SIZE, SHARE | GROWTH REPORT [2032]
4. PubMed: Home-based high tone therapy may alleviate chemotherapy ...
5. DrugBank: Hydrocortisone: Uses, Interactions, Mechanism of Action - DrugBank